Design and synthesis of new dual binding site cholinesterase inhibitors: In vitro inhibition studies with in silico docking

Letters in Drug Design and Discovery

Volumn 11, Issue 3, 2014, Pages 331-338

  Yar, Muhammad ^a   Bajda, Marek ^b   Mehmood, Rana Atif ^c   Sidra, Lala Rukh ^a   Ullah, Nisar ^d   Shahzadi, Lubna ^a   Ashraf, Muhammad ^e   Ismail, Tayaba ^e   Shahzad, Sohail Anjum ^f   Khan, Zulfiqar Ali ^g   Naqvi, Syed Ali Raza ^g   Mahmood, Nasir ^h  

^a Process and Energy Systems Engineering Center PRESTIGE   (Pakistan)

^b UNIVERSITY OF WARSAW   (Poland)

^c GC UNIVERSITY   (Pakistan)

^d KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

^e THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^f University of Health Sciences ^*  (Pakistan)

^g GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^h UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Hydrazides; Indole derivatives; Molecular docking; SAR

Indexed keywords

EID: 84893807737     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/15701808113106660078     Document Type: Article

References (39)

1. Walsh, D.M.; Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron, 2004, 44, 181-193.
2. Alzheimer's Disease International. World Alzheimer Report 2010: The Global Economic Impact of Dementia.London:http://www.alz.org/documents/national/ world-alzheimer-report-2010.pdf (Accessed Sep 06, 2013).
3. Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J. Neurol. Neurosurg. Psychiatry, 1999; 66, 137-147
4. Leonetti, F.; Catto, M.; Nicolotti, O.; Pisani, L.; Cappa, A.; Stefanachi, A.; Carotti, A. Homo- and hetero-bivalent edrophonium-like ammonium salts as highlypotent, dual binding site AChE inhibitors,Bioorg. Med. Chem., 2008, 16, 7450-7456.
5. Akasofu, S.; Kimura, M.; Kosasa, I.; Sawada, K.; Ogura, H. Study of neuroprotectionof donepezil, a therapy for Alzheimer's disease. Chem. Biol. Interact., 2008,175, 222-226.
6. Sheng, R.; Lin, X.; Li, J.Y.; Jiang, Y.K.; Shang, Z.C.; Hu, Y.Z. Design, synthesis, andevaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 3834-3837.
7. He, X.-C.; Feng, S.; Wang, Z.-F.; Shi, Y.; Zheng, S.; Xia, Y.; Jiang, H.; Tang, X.-C.; Bai, D. Study on dual-site inhibitors of acetylcholinesterase: highly potent derivatives of bis- and bifunctional huperzine B. Bioorg. Med. Chem., 2007, 15, 1394-1408.
8. Dinamarca, M.C.; Weinstein, D.; Monasterio, O.; Inestrosa, N.C. The synaptic protein neuroligin-1 interacts with the amyloid β-peptide. Is there a role in Alzheimer's disease? Biochemistry, 2011, 50, 8127-8137.
9. Holmstedt, B. Distribution and determination of cholinesterases in mammals. Bull. Org. Mond. Sante., 1971, 44, 99.
10. Lawson, A.A.; Barr, R.D. Acetylcholinesterase in red blood cells. Am. J. Hematol., 1987, 26, 101-112.
11. Barr, R.D.; Koekebakker, M.; Lawson, A.A. Acetylcholinesterase in the human erythron. II. Biochemical assay. Am. J. Hematol., 1988, 28, 260-265.
12. Dekoski, S.T. Pathology and pathways of Alzheimer's disease with an update on new development and treatment. J. Am. Geriatr. Soc., 2003, 51, 314-320.
13. Tariot P.N.; Federoff, H.J. Current treatment for Alzheimer's disease and future prospects. Alzheimer.Dis. Assoc. Disord., 2003, 17, 105-113.
14. Kurz, A. The therapeutical potential of tacrine. J. Neural.Transm., Suppl. 1998, 54, 295-299.
15. Sugimoto, H. Donepezil hydrochloride: A treatment drug for Alzheimer's disease. Chem. Rec. 2001, 1, 63-73.
16. Jann, M.W. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy, 2000, 20, 1-12.
17. Zarotsky, V.; Sramek, J.J.; Cutler, N.R. Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health-Syst. Pharm., 2003, 60, 446-452.
18. Qizilbash, N., Birks, J., Lopez Arrieta, J., Lewington, S., Szeto, S., Withdrawn: Tacrine for Alzheimer's disease. Cochrane Database Syst. Rev., 2007, 18(3), CD000202.
19. Sugimoto, H. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis, Chem. Biol. Interact. 2008, 175, 204-208.
20. Smith, C.P.; Bores, G.M.; Petko, W.; Li,M.; Selk, D.E.; Rush, D.K.; Camacho, F.; Winslow, J.T.; Fishkin, R.; Cunningham, D.M.; Brooks, K.M.; Roehr, J.; Hartman, H.B.; Davis, L.; Vargas, H.M. Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease, J. Pharmacol. Exp. Ther., 1997, 280, 710-720.
21. Marco-Contelles, J.; Leon, R.; de los Rios, C.; Garcia, A.G.; Lopez, M.G.; Villarroya, M. New multipotent tetracyclic tacrines with neuroprotective activity. Bioorg. Med. Chem., 2006, 14, 8176-8185.
22. de los Rios, C.; Marco, J.L.; Carreiras, M.D.C.; Chinchon, P.M.; Garcia, A.G.; Villarroya, M. Novel tacrine derivatives that block neuronal calcium channels. Bioorg. Med. Chem., 2002, 10, 2077-2088.
23. Jones, E.L.; Mok, K.; Hanney, M.; Harold, D.; Sims, R.; Williams, J.; Ballard, C. Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. Neurobiol. Aging, 2013, 34, 2441-2441.
24. Inman, M.; Moody, C.J.; Indole synthesis - something old, something new. Chem. Sci., 2013, 4, 29-41.
25. Yar, M.; Arshad, M.; Akhtar, M. N.; Shahzad, S.A.; Khan, I.U.; Khan, Z. A.; Ullah, N.; Ninomiya, I., Studies towards the synthesis of (±)-reserpine: Photocyclization mediated a novel and efficient synthesis of 11, 18-dimethoxy-(20α)-18, 19-didehydro-yohimban-17-one. Eur. J. Chem., 2012, 3, 26-31.
26. del Monte-Millán, M.; García-Palomero, E.; Valenzuela, R.; Usán, P.; de Austria, C.; Muñoz-Ruiz, P.; Rubio, L.; Dorronsoro, I.; Martínez, A.; Medina, M. Dual binding site acetylcholinesterase inhibitors. J. Mol. Neurosci., 2006, 30, 85-87
27. Ismail, M.M.; Kamel, M.M.; Mohamed L.W.; Faggal S.I.Synthesis of new indole derivatives structurally related to donepezil and their biological evaluation as acetylcholinesterase inhibitors. Molecules, 2012, 17, 4811-4823.
28. Munoz-Ruiz, P.M.; Rubio, L.; Garcia-Palomero, E.; Dorronsoro, I.; del Monte-Millan, M.; Valenzuela, R.; Usan, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F.J.; Medina, M.; Martinez, A, Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J. Med. Chem., 2005, 48, 7223-7233.
29. Boga, M.; Kolak, U.; Topcu, G.; Bahadori, F.; Kartal, M.; Farnsworth, N.R. Two new indole alkaloids from Vincaherbacea L. Phytochem. Lett. 2011, 4, 399-403.
30. Jakubowska, A.; Kulig, K.; Guzior, N.; Malawska, B. Synthesis of novel N-benzyl substituted piperidine amides of 1H-indole-5-carboxylicacid as potential inhibitors of cholinesterases. Acta Pol. Pharm. Drug Res., 2012, 69, 449-455.
31. Yar, M.; Sidra, L.; Pontiki, E.; Mushtaq, N.; Ashraf, M.; Nasar, R.; Khan, I.U.; Mahmood, N.; Naqvi, S. A.R.; Khan, Z.A.; Shahzad, S.A. Synthesis, in vitro lipoxygenase inhibition, docking study and thermal stability analyses of novel indole derivatives. J. Iran Chem. Soc., 2013, DOI 10.1007/s13738-013-0308- 3.
32. Ellman, G.L.; Courtney, K.D.; Andres, V.; Featherstone, R.M.; a new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7, 88-95.
33. Triggle, D.J.; Mitchell, J.M.; Filler, R. The pharmacology of physostigmine. CNS Drug Rev., 1998, 4(2), 87-136.
34. Online Demo-Corina, http://www.molecular-networks.com/online-demos/ corina-demo (10April 2013)
35. Sybyl 8.0, Tripos, St. Louis, MO, USA, 2007.
36. Protein Data Bank, http://www.pdb.org (10 April 2013)
37. Gold 5.1, The Cambridge Crystallographic Data Centre, Cambridge, UK, 2011
38. PyMOL 0.99rc6, DeLano Scientific LLC: Palo Alto, CA, USA, 2006.
39. Bajda, M.; Wieckowska, A.; Hebda, M.; Guzior, N.; Sotriffer, C.A.; Malawska, B. Structure-based search for new inhibitors of cholinesterases. Int. J. Mol. Sci., 2013, 14, 5608-5632.